Last updated 4 days ago

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 patients around the world
Available in Brazil, United States
The study consists of a screening period (up to 28 days), a treatment period with 21-day cycles, and an after-treatment period that includes a 30-day safety follow-up period and a long-term survival follow-up period. Treatment continues until the cancer clearly gets worse (in scans, based on blinded independent central review [BICR] assessment or investigator's decision), side effects become unacceptable, the participant chooses to stop, or the study ends. Participants are put into one of two groups in a 1:1 ratio, which means they will have an equal chance to be in either treatment group, i.e., BNT324 group, or docetaxel plus prednisone/prednisolone group (current SoC). An independent committee will help ensure participant safety, by regularly reviewing safety and early results. For each participant, the treatment and follow-up periods are projected to be up to ~58 months.
BioNTech SE
1Research sites
736Patients around the world

This study is for people with

Prostate cancer
Castration resistant prostate cancer

Requirements for the patient

From 18 Years
Male

Medical requirements

Are male adults (defined as ≥18 years of age or of an acceptable age according to local regulations at the time of giving informed consent).
Must have documented progressive prostate cancer based on at least one of the following criteria.
Serum/plasma PSA progression, by local laboratory, defined as two consecutive increases in PSA over a previous reference value, each measured sequentially at least 1 week apart. The PSA value at screening is required to be ≥1.0 ng/mL.
Radiographic soft tissue progression as per PCWG3-modified RECIST v1.1.
Radiographic progression of bone disease: evaluable disease or new bone lesion(s) by bone scan per PCWG3 criteria.
Had previously received one or two prior androgen receptor pathway inhibitor treatments and experienced disease progression during or after a minimum of 8 weeks of therapy.
Must not have received systemic cytotoxic chemotherapy, including taxane-based chemotherapy, for mCRPC.
Must have had prior orchiectomy and/or have ongoing androgen-deprivation therapy and a castrate-level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L). Participant being treated with luteinizing hormone-releasing hormone agonists or antagonists must continue such treatment throughout the study.
Must have an Eastern Cooperative Oncology Group performance score of 0 or 1.
Have received prior treatment with B7-H3 targeted therapy, including B7-H3 ADCs.
Have uncontrolled or significant cardiovascular disease, as defined in the protocol.
Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids or have current ILD/pneumonitis.

Sites

Hospital Moinhos de Vento - Porto Alegre
Recruiting
R. Ramiro Barcelos, 910 - Floresta, Porto Alegre - RS, 90035-001, Brazil
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy